

Malignant Hematology Areas of Interest (Investigator Initiated Studies and Research Collaborations)

REGN1979 (CD20xCD3) odronextamab

Non-interventional proposals:

- Investigating tumor and immune correlates of response to CD20xCD3 bispecific antibodies in B-NHL

Interventional proposals:

- Novel treatment combinations, including combinations with novel agents targeting non-redundant pathways, in all lines of therapy for the treatment of b-NHL
- Sequencing Odronextamab in the treatment paradigm for the treatment of B-NHL
- Investigating Odronextamab in hard-to-treat, medically unaddressed, and rare populations with Lymphomas in high unmet medical needs
- Predictors of response and/or (primary or acquired) resistance to Odronextamab in the treatment of b-NHL

Note that we cannot currently accept any proposals for Investigator Sponsored Studies or Research Collaborations using odronextamab in the European Union.

(v4.0 17Jan2023)

REGN5458 (BCMA x CD3 bispecific antibody)

Non-interventional proposals in Plasma Cell Dyscrasias exploring:

- Biomarkers leading to better characterization, management, and treatment options
 - BCMA expression pre and post treatment (standard of care agents or novel agents)
 - Early disease progression and/or mechanisms of resistance
 - T cell phenotyping in biopsy and aspirate
 - Plasma cell markers associated with progression/resistance to standard of care
 - Immune subset characterization including T cell suppressive mechanisms
 - Biomarkers for future therapeutic target development
 - Biomarkers of Plasma Cell Dyscrasias
- Models to assess functional immune responsiveness to BCMA x CD3
- Experimental models to explore novel combinations with BCMA x CD3

Note that we cannot currently accept any proposals for Investigator Sponsored Studies or Research Collaborations using REGN5458 in the European Union.

(v3.0, 19Sep2022)